تاسيجنا 200مجم 28 كبسول

ما هو دواء تاسيجنا 200مجم 28 كبسول

جرعة دواءتاسيجنا 200مجم 28 كبسول

يستعمل دواء تاسيجنا 200مجم 28 كبسولtasigna 200 mg 28 caps. anti-tumors anti-tumors

indication for the potential treatment of various leukemias including chronic myeloid leukemia (cml). -pharmacodynamics nilotinib is a transduction inhibitor that targets bcr-abl c-kit and pdgf for the potential treatment of various leukemias including chronic myeloid leukemia (cml). -mechanism of action chronic myelogenous leukaemia (cml) is caused by the bcr-abl oncogene. nilotinib inhibits the tyrosine kinase activity of the bcr-abl protein. nilotinib fits into the atp-binding site of the bcr-abl protein with higher affinity than imatinib over-riding resistance caused by mutations. the ability of amn107 to inhibit tel-platelet-derived growth factor receptor-beta (tel-pdgfrbeta) which causes chronic myelomonocytic leukaemia and fip1-like-1-pdgfralpha which causes hypereosinophilic syndrome suggests potential use of amn107 for myeloproliferative diseases characterised by these kinase fusions (stover et al 2005; weisberg et al 2005). amn107 also inhibits the c-kit receptor k

تركيبة دواءتاسيجنا 200مجم 28 كبسولtasigna 200 mg 28 caps.

يتركب هذا الدواء من :nilotinib